- Home
- RGTI vs IBRX Comparison
RGTI vs IBRX Comparison
Compare RGTI & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGTI
- IBRX
- Stock Information
- Founded
- RGTI 2013
- IBRX 2014
- Country
- RGTI United States
- IBRX United States
- Employees
- RGTI N/A
- IBRX N/A
- Industry
- RGTI Retail: Computer Software & Peripheral Equipment
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RGTI Technology
- IBRX Health Care
- Exchange
- RGTI Nasdaq
- IBRX Nasdaq
- Market Cap
- RGTI 2.4B
- IBRX 2.4B
- IPO Year
- RGTI N/A
- IBRX N/A
- Fundamental
- Price
- RGTI $10.58
- IBRX $2.07
- Analyst Decision
- RGTI Strong Buy
- IBRX Strong Buy
- Analyst Count
- RGTI 4
- IBRX 5
- Target Price
- RGTI $14.50
- IBRX $11.35
- AVG Volume (30 Days)
- RGTI 27.6M
- IBRX 8.6M
- Earning Date
- RGTI 05-12-2025
- IBRX 05-16-2025
- Dividend Yield
- RGTI N/A
- IBRX N/A
- EPS Growth
- RGTI N/A
- IBRX N/A
- EPS
- RGTI N/A
- IBRX N/A
- Revenue
- RGTI $10,790,000.00
- IBRX $14,745,000.00
- Revenue This Year
- RGTI $32.30
- IBRX $579.28
- Revenue Next Year
- RGTI $139.90
- IBRX $179.96
- P/E Ratio
- RGTI N/A
- IBRX N/A
- Revenue Growth
- RGTI N/A
- IBRX 2270.58
- 52 Week Low
- RGTI $0.66
- IBRX $1.83
- 52 Week High
- RGTI $21.42
- IBRX $9.16
- Technical
- Relative Strength Index (RSI)
- RGTI 59.79
- IBRX 36.78
- Support Level
- RGTI $9.14
- IBRX $1.83
- Resistance Level
- RGTI $10.92
- IBRX $2.63
- Average True Range (ATR)
- RGTI 0.75
- IBRX 0.19
- MACD
- RGTI 0.17
- IBRX -0.05
- Stochastic Oscillator
- RGTI 87.84
- IBRX 23.08
About RGTI Rigetti Computing Inc.
Rigetti Computing Inc is engaged in the business of full-stack quantum computing. The company offers full-stack quantum computing platform as a cloud service to a wide range of end-users, directly through its Rigetti QCS platform, and also through cloud service providers. Its proprietary quantum-classical infrastructure provides ultra-low latency integration with public and private clouds for high-performance practical quantum computing. The company has developed the industry's first multi-chip quantum processor for scalable quantum computing systems. Geographically, the company derives the majority of its revenue from the United States.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.